App-Quantinova.ai

Moderate dose serial therapy for aged and resistant patients with cholangiocarcinomas.

Howard Bruckner - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Advanced biliary tract carcinoma

Docetaxel

A phase (Ph) 1b/2 study of ribociclib (R) in combination with docetaxel (D) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC).

Ivan de Kouchkovsky - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Docetaxel

Paclitaxel versus docetaxel-based neoadjuvant chemotherapy and risk of lymphedema in breast cancer patients.

Yirong Zhu - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Docetaxel

Trastuzumab biosimilar (Kanjinti) in breast cancer patients: One-center retrospective observational study.

Agnieszka I. Jagiello-Gruszfeld - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Docetaxel

Real-world data (RWD) reveals benefit for adjuvant chemotherapy with docetaxel, oxaliplatin and fluorouracil/leucovorin (FLOT) is limited to those with tumour regression grade (TRG) ≥3 in oesophago-gastric cancer (OGC).

Brindley Sonal Hapuarachi - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastric Cancer

Docetaxel

Cardiac and skeletal muscle energetic pathways following anthracycline chemotherapy for breast cancer

David Gamble - British Cardiovascular Society (BCS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Docetaxel

Antibody Drug Conjugates for Non-small Cell Lung Cancer

H. Hayashi - IASLC World Conference on Lung Cancer (IASLC WCLC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Triple-negative breast cancer

Docetaxel

Computational Omics Biology Model (CBM) Identifies Novel Biomarkers to Inform Combination Platinum Compound Therapy in NSCLC

V. Velcheti - IASLC World Conference on Lung Cancer (IASLC WCLC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Docetaxel

Vibostolimab Plus Pembrolizumab With/Without Docetaxel vs Docetaxel in NSCLC After Platinum Chemotherapy and Immunotherapy

S. Peters - IASLC World Conference on Lung Cancer (IASLC WCLC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Brain metastasis

Docetaxel

RATIONALE-303 Phase 3 Tislelizumab vs Docetaxel in Previously Treated Advanced NSCLC: China Subgroup Analysis

Y. Fan - IASLC World Conference on Lung Cancer (IASLC WCLC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Docetaxel

Sintilimab Plus Docetaxel in Previously Treated Advanced NSCLC, Updates on Progression-Free and Overall Survival

Z. Wang - IASLC World Conference on Lung Cancer (IASLC WCLC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Docetaxel

Extended Resections for Advanced Stages T3/T4 NSCLC After Neoadjuvant Treatment: Conclusions of SAKK Pooled Analysis (16/96, 16/00, 16/01)

K. Furrer - IASLC World Conference on Lung Cancer (IASLC WCLC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Docetaxel

Capmatinib vs Docetaxel in Pretreated Patients With MET Exon 14 Skipping–mutated Stage IIIB/IIIC or IV NSCLC (GeoMETry-III)

P. Souquet - IASLC World Conference on Lung Cancer (IASLC WCLC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Brain metastasis

Docetaxel

Anlotinib Plus Docetaxel vs Docetaxel for 2nd-Line Treatment of EGFR negative NSCLC (ALTER-L018): A Randomized Phase II Trial

L. Wu - IASLC World Conference on Lung Cancer (IASLC WCLC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Docetaxel

Concomitant Fibrates and Immunotherapy in Non-Small Cell Lung Cancer Patients in the Veterans Health Administration

W. Stokes - IASLC World Conference on Lung Cancer (IASLC WCLC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Docetaxel

Delivering docetaxel and curcumin via a nano-combination-therapy for modulating the progression of neuroblastoma

Agnese Fragassi - American Association for Cancer Research (AACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Neuroblastoma

Docetaxel

KMT2D and PIK3CA mutation as potential factors to predict adjuvant chemotherapy efficacy in surgical triple negative breast cancer

Xue Wang - American Association for Cancer Research (AACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Triple-negative breast cancer

Docetaxel

Clinical and genomic correlates of survival outcomes in patients (pts with metastatic castration-sensitive prostate cancer (mCSPC receiving intensified androgen deprivation therapy (ADT in a real-world population

Nicolas Sayegh - American Association for Cancer Research (AACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Prostate cancer

Docetaxel

Tislelizumab (TIS versus docetaxel (D in patients with previously treated advanced non-squamous (non-sq non-small-cell lung cancer (NSCLC: Subanalysis from the RATIONALE-303 phase 3 randomized clinical study

Ying Cheng - American Association for Cancer Research (AACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Docetaxel

Tislelizumab (TIS versus docetaxel (D in patients with previously treated advanced squamous (sq non-small-cell lung cancer (NSCLC: Sub-analysis from phase 3 RATIONALE-303 randomized clinical study

Jie Wang - American Association for Cancer Research (AACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Docetaxel

Filters

2459 Abstracts